Stay updated with breaking news from Ongoing Phase. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Regulatory progress for govorestat for the treatment of Classic Galactosemia, with potential NDA submission based on discussions with the FDA as well as EMA Marketing Authorization Application... -Today at 07:04 am- MarketScreener
Positive Review from the Drug Safety Monitoring Board (DSMB) on the Ongoing Phase 2 Clinical Trial in Ulcerative Colitis. Positive Opinion for Orphan Drug Designation from the European Medicines Agency in the
Ongoing Phase IIb study expands to arm B5-year results of phase I study confirm efficacy and safety of novel immune-tolerance inducing cell therapy in organ transplantationSecond closing of Series A
Brii Biosciences has acquired worldwide exclusive license to VBI-2601 and an exclusive license for PreHevbri® in the Asia Pacific region VBI will receive gross proceeds of $15 million in upfront payments, subject to near-term milestone achievements, including an equity investment of approximately $3 million VBI is eligible to receive up to $422 million in additional potential regulatory and commercial milestone payments, plus double-digit royalties
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul 5, 2023--